Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Kidneys in heart failure: Impact of flozins and beyond
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97844. Online ahead of print.ABSTRACTChronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related. According to the concept of cardio-renal and reno-cardiac syndromes most of patients with CKD are affected by cardiovascular disease (CVD) and CVD (including HF) is one of the factors not only promoting progression of established CKD, but also triggering its onset and development. Treatment of CVD and HF in CKD patients remains to be challenging since CKD patients are characterized by extremely diverse and strongly expressed risk profile...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Tomasz Stomp ór Agata Winiarska Source Type: research
Sacubitril/valsartan compared to ramipril in high ‐risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial
ConclusionsUse of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post MI setting in patients with LVSD and/or congestion.This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - November 7, 2023 Category: Cardiology Authors: Morten Schou,
Brian Claggett,
Zi Michael Miao,
Alberto Fernandez,
Gerasimos Filippatos,
Christopher Granger,
Karola Jering,
Aldo P. Maggioni,
Finnian McCausland,
Julio Nu ñez Villota,
Jean‐Lucien Rouleau,
Freny Vaghaiwalla Mody,
Peter van d Tags: Research Article Source Type: research
Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensi ón Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)
Arch Cardiol Mex. 2023;93(Supl):1-12. doi: 10.24875/ACM.23000036.ABSTRACTHeart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use ...
Source: Archivos de Cardiologia de Mexico - November 2, 2023 Category: Cardiology Authors: Mario Speranza Clara Saldarriaga Carlos E Ramos Daniel Quesada V íctor Rossel Jaime R Ventura-Umanzor Freddy Pow-Chon Walter Alarco Yolanda Figueroa Antonio Maga ña Juan E G ómez-Mesa David Rodr íguez-García Source Type: research
Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensi ón Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)
Arch Cardiol Mex. 2023;93(Supl):1-12. doi: 10.24875/ACM.23000036.ABSTRACTHeart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use ...
Source: Archivos de Cardiologia de Mexico - November 2, 2023 Category: Cardiology Authors: Mario Speranza Clara Saldarriaga Carlos E Ramos Daniel Quesada V íctor Rossel Jaime R Ventura-Umanzor Freddy Pow-Chon Walter Alarco Yolanda Figueroa Antonio Maga ña Juan E G ómez-Mesa David Rodr íguez-García Source Type: research
Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensi ón Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)
Arch Cardiol Mex. 2023;93(Supl):1-12. doi: 10.24875/ACM.23000036.ABSTRACTHeart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use ...
Source: Archivos de Cardiologia de Mexico - November 2, 2023 Category: Cardiology Authors: Mario Speranza Clara Saldarriaga Carlos E Ramos Daniel Quesada V íctor Rossel Jaime R Ventura-Umanzor Freddy Pow-Chon Walter Alarco Yolanda Figueroa Antonio Maga ña Juan E G ómez-Mesa David Rodr íguez-García Source Type: research
Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensi ón Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)
Arch Cardiol Mex. 2023;93(Supl):1-12. doi: 10.24875/ACM.23000036.ABSTRACTHeart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use ...
Source: Archivos de Cardiologia de Mexico - November 2, 2023 Category: Cardiology Authors: Mario Speranza Clara Saldarriaga Carlos E Ramos Daniel Quesada V íctor Rossel Jaime R Ventura-Umanzor Freddy Pow-Chon Walter Alarco Yolanda Figueroa Antonio Maga ña Juan E G ómez-Mesa David Rodr íguez-García Source Type: research
